Alzheimer’s Drug Discovery Foundation

Upcoming ADDF Funding Opportunities!
*Next Deadline for Full Proposal is September 5th
*Letter of Intent is due two weeks prior to deadline

Open Requests For Proposals:

Accelerating the Path to Drug Development for Novel Mitochondria-Directed Therapies Program

Summary: Mitochondria dysfunction underlies many different diseases. The brain is particularly vulnerable to changes in energy utilization that occur with age or because of underlying disease pathology. Novel therapies that can correct defects in mitochondria functioning have the potential to impact many different diseases – from early childhood genetic diseases to late life neurodegenerative diseases such as Alzheimer’s disease. The Alzheimer’s Drug Discovery Foundation (ADDF) is partnering with the Foundation for Mitochondrial Medicine (FMM) to drive innovative translational research for mitochondrial dysfunction. See full RFP here.
General Request for Proposals (RFP)

Summary: The Alzheimer’s Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer’s disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co- sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation. See our 2013 Funding Priorities and full RFP here.
Program to Accelerate Clinical Trials (PACT) for Alzheimer’s Disease

Summary: The true test for new Alzheimer’s drugs is in human clinical trials. The ADDF has responded to this need by creating the Program to Accelerate Clinical Trials (PACT). The goal of the PACT RFP is to increase the number of innovative drugs tested in human clinical studies. This program will primarily fund biomarker-based pilot clinical trials for Alzheimer’s disease. See full RFP here.
The ADDF/Belfer ApoE Therapeutics Innovation Program

Summary: The Alzheimer’s Drug Discovery Foundation (ADDF) and the Robert and Renée Belfer Family Foundation established The ADDF/Belfer ApoE Therapeutics Innovation Program to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. This program will allow the ADDF to substantially build on its strategic investment in apoE drug discovery and development and will support both preclinical and clinical stage programs. See full RFP here.

For more information regarding the application process, please contact:
Reena Vanjani, Grants Manager
Phone: 212-901-8119 Email rvanjani@alzdiscovery.org